Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma

Published:2019-07-29 Issue:8 Volume:9 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Dhakal Binod,D’Souza Anita,Hamadani Mehdi,Arce-Lara Carlos,Schroeder Katrina,Chhabra Saurabh,Shah Nirav N.,Gauger Katelyn,Keaton Taylor,Pasquini Marcelo,Hari Parameswaran

Funder

Takeda Pharmaceutical Company Limited | Takeda Oncology

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-019-0219-3.pdf

Reference32 articles.

1. Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28, 1122–1128 (2014).

2. D’Souza, A. et al. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014. Leukemia 31, 1998–2000 (2017).

3. Cheson, B. D. & Rummel, M. J. Bendamustine: rebirth of an old drug. J. Clin. Oncol. 27, 1492–1501 (2009).

4. Leoni, L. M. The evolving role of bendamustine in lymphoid malignancy: understanding the drug and its mechanism of action-introduction. Semin. Hematol. 48, S1–S3 (2011).

5. Rummel, M. J. & Gregory, S. A. Bendamustine’s emerging role in the management of lymphoid malignancies. Semin. Hematol. 48, S24–S36 (2011).

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

2. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice;Cancers;2023-04-05

3. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2022-07

4. What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma;Targeted Oncology;2022-06-30

5. The roles of ubiquitination‐mediated intrinsic apoptotic signalling in cancer therapy;Clinical and Translational Discovery;2022-06